Parents' decisions to screen newborns for FMR1 gene expansions in a pilot research project

Pediatrics

Volumn 127, Issue 6, 2011, Pages

  Skinner, Debra ^a   Choudhury, Summer ^a   Sideris, John ^a   Guarda, Sonia ^a   Buansi, Allen ^a   Roche, Myra ^b   Powell, Cynthia ^b   Bailey Jr , Donald B ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

Informed consent; Newborn screening; Patient decision making; Screening tools

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; ETHNICITY; FAMILY DECISION MAKING; FEMALE; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENETIC SCREENING; HEALTH CARE PRACTICE; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; NEWBORN SCREENING; PILOT STUDY; PRIORITY JOURNAL;

ADULT; DECISION MAKING; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC TESTING; HUMANS; INFANT, NEWBORN; MALE; PARENTAL CONSENT; PARENTS; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 79957903589     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-3078     Document Type: Article

References (48)

1. Pelias MK, Markward NJ. Newborn screening, informed consent, and future use of archived tissue samples. Genet Test. 2001;5(3):179-185 (Pubitemid 34066160)
2. Baily MA, Murray TH. Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore, MD: The Johns Hopkins University Press; 2009
3. Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics. 2006;117(2):923-929 (Pubitemid 46063236)
4. Bailey DB Jr, Skinner D, Davis A, Whitmarsh I, Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics. 2008;121(3). Available at: www.pediatrics.org/cgi/content/full/121/3/e693
5. Botkin JR. Research for newborn screening: developing a national framework. Pediatrics. 2005;116(4):862-871 (Pubitemid 44542812)
6. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117(5):1793-1799 (Pubitemid 46071411)
7. Kerruish NJ, Robertson SP. Newborn screening: new developments, new dilemmas. J Med Ethics. 2005;31(7):393-398 (Pubitemid 40945965)
8. Taylor HA, Wilfond BS. Ethical issues in newborn screening research: lessons from the Wisconsin cystic fibrosis trial. J Pediatr. 2004;145(3):292-296 (Pubitemid 39165673)
9. Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51(4):408-423
10. Hill MK, Archibald AD, Cohen J, Metcalfe SA. A systematic review of population screening for fragile X syndrome. Genet Med. 2010;12(7):396-410
11. Ross LF. Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A. 2006;140(8):914-922
12. Ross L. Ethical and policy issues in newborn screening: historical, current, and future developments. Neoreviews. 2009;10(2):e71-e81
13. Ronesi JA, Huber KM. Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci Signal. 2008;1(5):pe6
14. Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146A(16):2060-2069
15. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008;45(8):498-499
16. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001;3(5):359-371
17. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97(3):189-194 (Pubitemid 32059206)
18. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Mental Retard Dev Disabil Res Reviews. 2004;10(1):25-30 (Pubitemid 38375350)
19. Bourgeois JA, Coffey SM, Rivera SM, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry. 2009;70(6):852-862
20. Boyle L, Kaufmann WE. The behavioral phenotype of FMR1 mutations. Am J Med Genet C Semin Med Genet. 2010;154C(4):469-476
21. Chonchaiya W, Utari A, Pereira GM, Tassone F, Hessl D, Hagerman RJ. Broad clinical involvement in a family affected by the fragile X premutation. J Dev Behav Pediatr. 2009;30(6):544-551
22. Cunningham CL, Martinez Cerderno V, Navarro Porras E, et al. Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet. 2011;20(1):64-79
23. Bailey DB Jr, Raspa M, Bishop E, Holiday D. No change in the age of diagnosis for fragile X syndrome: findings from a national survey. Pediatrics. 2009;124(2):527-533
24. Skinner D, Sparkman KL, Bailey DB Jr. Screening for fragile X syndrome: parent attitudes and perspectives. Genet Med. 2003;5(5):378-384 (Pubitemid 37264987)
25. Bailey DB Jr, Skinner D, Warren SF. Newborn screening for developmental disabilities: Reframing presumptive benefit. Am J Public Health. 2005;95(11):1889-1893 (Pubitemid 41572356)
26. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system. Genet Med. 2006;8(5 suppl):12S-252S
27. Wilfond BS, Parad RB, Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr. 2005;147(3 suppl):S109-S113 (Pubitemid 41403281)
28. Bailey DB Jr, Skinner D, Sparkman KL. Discovering fragile X syndrome: family experiences and perceptions. Pediatrics. 2003;111(2):407-416 (Pubitemid 36177163)
29. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10(1):43-49 (Pubitemid 351184834)
30. Bernard HR, Ryan G. Analyzing Qualitative Data: Systematic Approaches. Thousand Oaks, CA: Sage Publications; 2010
31. Patton M. Qualitative Research and Evaluation Methods. 3rd ed. Thousand Oaks, CA: Sage Publications; 2002
32. Skinner D, Rodriguez P, Bailey DB. Qualitative analysis of Latino parents' religious interpretations of their child's disability. J Early Interv. 1999;22(4):271-285
33. Comeau AM, Levin DE. Population-based research within a public health service. In: Baily MA, Murray TH, eds. Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore, MD: The Johns Hopkins University Press; 2009:274-291
34. Feuchtbaum L, Lorey F, Faulkner L, et al. California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry. Pediatrics. 2006;117(5 pt 2):S261-S269 (Pubitemid 46071313)
35. Ross LF, Acharya K. Policy considerations in designing a fragile X population screening program. Genet Med. 2008;10(10):711-713
36. Saul RA, Friez M, Eaves K, et al. Fragile X syndrome detection in newborns-pilot study. Genet Med. 2008;10(10):714-719
37. Acharya K, Ackerman PD, Ross LF. Pediatricians' attitudes toward expanding newborn screening. Pediatrics. 2005;116(4):e476
38. Hiraki S, Ormond KE, Kim K, Ross LF. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children. Am J Med Genet A. 2006;140(21):2312-2319 (Pubitemid 44684957)
39. Campbell E, Ross LF. Parental attitudes regarding newborn screening of PKU and DMD. Am J Med Genet A. 2003;120A(2):209-214 (Pubitemid 37063798)
40. Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. Arch Intern Med. 2002;162(21):2458-2463 (Pubitemid 35340462)
41. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999;14(9):537-546 (Pubitemid 29441632)
42. Furr LA. Perceptions of genetics research as harmful to society: differences among samples of African-Americans and European-Americans. Genet Test. 2002;6(1):25-30 (Pubitemid 34620111)
43. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008;31(1):127-132 (Pubitemid 351822560)
44. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008;4(4):256-263 (Pubitemid 351419125)
45. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293-302
46. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46(4):266-271
47. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010;10:91
48. Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr. 2010;31(7):564-581